June Approval Likely for Chugai’s NTRK-Gene Targeting Entrectinib, 2nd Tumor-Agnostic Drug

Chugai Pharmaceutical’s ROS1/TRK inhibitor entrectinib is expected to land Japanese regulatory approval as early as June after it gained the backing of an all-important health ministry panel on May 30 for the treatment of NTRK gene fusion-positive solid tumors. If...read more